Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-Adapted Therapy for High-Risk DLBCL
NCT00712582Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2008
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, ifosfamide, etoposide, carboplatin in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), follicular lymphoma (FL), sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 2008; status: completed.
02
Drugs
rituximabifosfamideetoposidecarboplatin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00712582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00712582.